p.79 抽出テキスト

398. Yamashita T, Akao M, Atarashi H, et al. Effect of polypharmacy on clinical outcomes in elderly patients with non-valvular atrial fibrillation ― a sub-analysis of the ANAFIE registry. Circ J 2022; 87: 6-16. PMID: 35858804 399. Kuroda M, Tamiya E, Nose T, et al. Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation: a prespecified subanalysis of the ELDERCARE-AF randomized clinical trial. JAMA Cardiol 2022; 7: 583-590. PMID: 35416910 400. Yoshida T, Nakamura A, Funada J, et al. Efficacy and safety of edoxaban 15 mg according to renal function in very elderly patients with atrial fibrillation: a subanalysis of the ELDERCARE-AF trial. Circulation 2022; 145: 718-720. PMID: 35226559 401. Wang M, Zeraatkar D, Obeda M, et al. Drug-drug interactions with warfarin: a systematic review and meta-analysis. Br J Clin Pharmacol 2021; 87: 4051-4100. PMID: 33769581 402. Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020; 9: e017559. PMID: 32538234 403. Scotti P, Séguin C, Lo BWY, et al. Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes. J Neurosurg 2019; 1-10. PMID: 31277068 404. Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019; 381: 1103-1113. PMID: 31475793 405. Kaikita K, Yasuda S, Akao M, et al. Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial. Circ Cardiovasc Interv 2021; 14: e010476. PMID: 34474583 406. Matsuzawa Y, Kimura K, Yasuda S, et al. Antithrombotic therapy for atrial fibrillation and coronary artery disease in patients with prior atherothrombotic disease: a post hoc analysis of the AFIRE trial. J Am Heart Assoc 2021; 10: e020907. PMID: 34658247 407. Yazaki Y, Nakamura M, Iijima R, et al. Clinical outcomes of rivaroxaban monotherapy in heart failure patients with atrial fibrillation and stable coronary disease: insights from the AFIRE trial. Circulation 2021; 144: 1449-1451. PMID: 34694893 408. Ishii M, Akao M, Yasuda S, et al. Rivaroxaban monotherapy in patients with atrial fibrillation and coronary stenting at multiple vessels or the left main trunk: the AFIRE trial subanalysis. J Am Heart Assoc 2022; 11: e027107. PMID: 36285792 409. Matoba T, Yasuda S, Kaikita K, et al. Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights from the AFIRE trial. JACC Cardiovasc Interv 2021; 14: 2330- 2340. PMID: 34736731 410. Själander S, Själander A, Svensson PJ, et al. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Europace 2014; 16: 631-638. PMID: 24158253 411. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498. PMID: 32860505 412. Okumura K, Akao M, Yoshida T, et al.  Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020; 383: 1735-1745. PMID: 32865374 413. Akashi S, Oguri M, Ikeno E, et al. Outcomes and safety of very-lowdose edoxaban in frail patients with atrial fibrillation in the ELDER- CARE-AF randomized clinical trial. JAMA Netw Open 2022; 5: e2228500. PMID: 35997978 414. Okazaki O, Higashino Y, Yokoya K, et al. Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis. Am Heart J 2022; 250: 66-75. PMID: 35568194 415. Mikami T, Hirabayashi K, Okawa K, et al. Laboratory test predictors for major bleeding in elderly ( ≥80 years) patients with nonvalvular atrial fibrillation treated with edoxaban 15 mg: sub-analysis of the ELDERCARE-AF trial. J Am Heart Assoc 2022; 11: e024970. PMID: 36056729 416. Ide Y, Ogawa H, Ishigami K, et al. Clinical characteristics and outcomes of very elderly patients with atrial fibrillation at high bleeding risk ― the Fushimi AF registry. Circ Rep 2021; 3: 629-638. PMID: 34805602 417. Okumura K, Yamashita T, Akao M, et al. Oral anticoagulants in very elderly nonvalvular atrial fibrillation patients with high bleeding risks: ANAFIE registry. JACC Asia 2022; 2: 720- 733. PMID: 36444326 418. Connolly SJ, Crowther M, Eikelboom JW, et al. ANNEXA- 4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380: 1326-1335. PMID: 30730782 419. Milling TJ Jr, Middeldorp S, Xu L, et al. ANNEXA-4 Investigators. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation 2023; 147: 1026-1038. PMID: 36802876 420. Gómez-Outes A, Alcubilla P, Calvo-Rojas G, et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J Am Coll Cardiol 2021; 77: 2987-3001. PMID: 34140101 421. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 2017; 377: 431-441. PMID: 28693366 422. Lu G, Conley PB, Leeds JM, et al. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood Adv 2020; 4: 728- 739. PMID: 32092140 423. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J 2015; 36: 1831-1838. PMID: 25939649 424. Elayi CS, Shohoudi A, Moodie E, et al. AF-CHF Investigators. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: an AF-CHF analysis. Int J Cardiol 2020; 313: 48-54. PMID: 32320783 425. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. Eur Heart J 2013; 34: 1481-1488. PMID: 23186806 426. Fauchier L, Grimard C, Pierre B, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009; 103: 248-254. PMID: 19121446 427. 日本循環器学会/日本心不全学会.2021 年 JCS/JHFS ガイドライン フォーカスアップデート版 急性・慢性心不全診療.https://www.j-circ.or.jp/

cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf 428. Kotecha D, Bunting KV, Gill SK, et al. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial. JAMA 2020; 324: 2497-2508. PMID: 33351042 429. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878. PMID: 12588271 430. Kotecha D, Holmes J, Krum H, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235-2243. PMID: 25193873 431. Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351: h4451. PMID: 26321114 432. 日本循環器学会.2020 年版 心アミロイドーシス診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/ 2020/ 02/ JCS2020_Kitaoka.pdf 433. Ettinger PO, Wu CF, De La Cruz C Jr, et al. Arrhythmias and the “Holiday Heart”: alcohol-associated cardiac rhythm disorders. Am Heart J 1978; 95: 555-562. PMID: 636996 434. Liang Y, Mente A, Yusuf S, et al. ONTARGET and TRANSCEND Investigators. Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CMAJ 2012; 184: E857-E866. PMID: 23027910 435. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: how much is too much? J Am Coll Cardiol 2014; 64: 290-292. PMID: 25034066 436. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol 2014; 64: 281-289. PMID: 25034065 437. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100. PMID: 20299623 438. Overvad TF, Rasmussen LH, Skjøth F, et al. Alcohol intake and prognosis of atrial fibrillation. Heart 2013; 99: 1093- 1099. PMID: 23766449 439. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med 2020; 382: 20-28. PMID: 31893513 440. Prineas RJ, Jacobs DR Jr, Crow RS, et al. Coffee, tea and VPB. J Chronic Dis 1980; 33: 67-72. PMID: 6153390 441. Cheng M, Hu Z, Lu X, et al. Caffeine intake and atrial fibrillation